ReviewOxford open neuroscience2026
Targeting the metabolic niche: vulnerabilities and opportunities in brain metastases.
Review in Oxford open neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain metastases are the most common intracranial tumor in adults, and most arise from lung, breast, or melanoma. We propose a conceptual framework organized around three requirements for colonization, each unevenly distributed across the brain: vascular access, metabolic substrate, and escape from immune surveillance. We organize the literature around this three-axis framework and argue that metabolism, though the least exploited clinically, is where personalization may deliver the largest near-term gains. We review how lung, breast, and melanoma metastases each pair a characteristic metabolic program with characteristic anatomical distributions. Building on this, we discuss how targeted metabolic therapy, primary cancer-informed prediction, and longitudinal modeling can bring metabolism into precision brain metastasis care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.